Manila Times Business
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia500,000-1 million people are estimated to be living with FSGS in the territories[1]Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481[2] million, plus royalties US$10 million (~AU$14.1 million2) upfront paymentUp to US$330 million (~AU$467 million2) in potential mileston
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
G7 leaders open summit talks on Ukraine and the Middle East as Zelenskyy joins in France
1h ago
Informa Markets and Thailand's Health Ministry Join Forces To Deliver a Successful Edition of International Healthcare Week 2026 in Bangkok
1h ago
Kanlaon Volcano emits ash anew
2h ago
Cape Verde holds Spain to a surprising 0-0 draw in the country's World Cup debut
2h ago